Research

by
CF Community, CF News, Research, Therapies
March 20, 2019

SOURCE: VERTEX Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis Mean absolute improvement in ppFEV1 of 13.8 percentage points from baseline at week 4 in people with...

by
CF Community, CF News, Research
March 20, 2019

Alcresta Therapeutics Receives 510(k) Clearance For Use of RELiZORB® in ChildrenRELiZORB, The Only Digestive Enzyme Cartridge for Patients Requiring Supplemental Enteral Nutrition, Now Cleared to Help Children Suffering from Fat MalabsorptionJuly 20, 2017 08:30 AM Eastern Daylight TimeWARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc., dedicated to developing...

by
Boomer Esiason Foundation, CF Community, CF News, Research, Therapies
March 20, 2019

SOURCE  Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)-Phase 2 data showed mean absolute improvements in ppFEV1 of 9.7 and 12.0 percentage points...

by
CF Community, CF News, Research, Therapies
March 19, 2019

SOURCE: Original Press Release Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled LevofloxacinGranted for Three Distinct Indications:  Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as well as in Patients with Nontuberculous MycobacteriaPre-NDA Discussion...